Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults-Reference-Cited by-同舟云学术

Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults

Published:2005-04-01 Issue:4 Volume:38 Page:417-425
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Moyle Graeme J,DeJesus Edwin,Cahn Pedro,Castillo Steve A,Zhao Henry,Gordon David N,Craig Charles,Scott Trevor R

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference12 articles.

1. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults.;Bartlett;AIDS,2001

2. The Assessing Patients Preferred Treatments (APPT-1) study.;Moyle;Int J STD AIDS,2003

3. The NEAT study: A 48-week open label study to compare the antiretroviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1 infected patients.;Rodriguez-French;J Acquir Immune Defic Syndr,2004

4. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1 infected patients.;Gathe,2004

5. Abacavir versus zidovudine combined with lamivudine and efavirenz for the treatment of antiretroviral therapy-naive HIV-1 infected adults (Study CNA30024).;DeJesus;Clin Infect Dis,2004

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of pre-antiretroviral treatment HIV-RNA on time to successful virological suppression and subsequent virological failure – two nationwide, population-based cohort studies;AIDS;2022-11-10

2. An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV;Expert Opinion on Pharmacotherapy;2022-01-24

3. Bio-click chemistry: a bridge between biocatalysis and click chemistry;RSC Advances;2022

4. Rapid Near Point-of-Care Assay for HLA-B*57:01 Genotype Associated with Severe Hypersensitivity Reaction to Abacavir;AIDS Research and Human Retroviruses;2021-12-01

5. Rapid, Near Point-of-Care Assay for HLA-B*57:01 Genotype Associated with Severe Hypersensitivity Reaction to Abacavir;2021-06-02